Global Dengue Vaccine Market

Dengue Vaccine Market Segmentation By Age Group (<6 years, 6-12 years and >12 years) and By End User (Hospital, Clinics, Government Establishments, Private Establishments, Ambulatory Surgical Centers and Others) - Global Industry Demand Analysis and Opportunity Assessment 2018-2027

Buy Now
Report ID: 2393 | Published On: Feb 09, 2023
Request Free Sample Copy

Global Dengue Market

Chapter 1 Preface

1.1 Report Description

1.1.1 Report Introduction

1.1.2 Target Audience

1.1.3 USP and Key Offerings

1.2 Research Scope

1.3 Market Segmentation

1.4 Research Methodology

1.4.1 Phase I – Secondary Research

1.4.2 Phase II – Primary Research

1.4.3 Phase III – Expert Panel Review

1.4.4 Assumptions

1.4.5 Approach Adopted Bottom-Up Approach Top down Approach

1.4.6 Data Triangulation

1.5 Research Assumptions

1.6 Data Sources

Chapter 2 Executive Summary

Chapter 3 Pipeline Analysis Of Dengue Vaccines

Chapter 4 Epidemiology Outlook Of Dengue Vaccines

4.1 Overview

 Chapter 5 Market Dynamics

5.1 Market Drivers

5.1.1 Rising Cases of Dengue

5.1.2 Affordability of Vaccine

5.2 Market Restraints

5.2.1 Lack of awareness

5.3 Opportunity

5.3.1 Clinical Development of Vaccines

Chapter 6 Global Dengue Vaccine Market Analysis, by Demography

6.1 Overview

6.2 Below 5 years

6.3 5-10 years

6.4 Above 10 years

Chapter 7 Global Dengue Vaccine Market Analysis, By End- User

7.1 Overview

7.2 Clinics

7.3 Hospital

7.4 Ambulatory Surgical Centers

7.5 Government/Private Institutes

7.6 Others

Chapter 8 Global Dengue Vaccine Market Analysis

8.1 Introduction

Chapter 9 North America Dengue Vaccine Market Analysis

9.1 Overview

Chapter 10 Europe Dengue Vaccine Market Analysis

10.1 Overview

Chapter 11 Asia Pacific Dengue Vaccine Market Analysis

11.1 Overview

Chapter 12 Latin America Dengue Vaccine Market Analysis

12.1 Overview

12.1.1 Latin America

Chapter 13 Middle East & Africa Dengue Vaccine Market Analysis

13.1 Overview

Chapter 14 Company Profiles

14.1 Sanofi

14.2 Merck & Co., Inc.

14.3 Institut Pasteur

14.4 Takeda Pharmaceutical Company Limited

14.5 GlaxoSmithKline Plc

Chapter 15 Global Strategy of The Companies

15.1 Overview

15.2 Dengue vaccine candidates currently in clinical trials

Market Segmentation Synopsis

By Age Group

The global dengue vaccine market has been segmented on the basis of age group into <6 years, 6-12 years and >12 years. >12 years segment is anticipated to hold the largest market share of around 54% in the year 2027 in the global dengue vaccine market. Additionally, >12 years segment is anticipated to cross nearly USD 680 million by the end of 2027 by growing at a significant CAGR over the forecast period. Further, the <6 years segment is estimated to grow with the highest CAGR of around 22% over the forecast period.

Dengue Vaccine Market Share

By End User

The global dengue vaccine market is segmented by end user into hospital, clinics, government establishments, private establishments, ambulatory surgical centers and others. The clinics segment registered a significant market share along with a value of around USD 48 million in the year 2018. Clinics are the healthcare facilities which primarily focuses on the care of outpatients. Operated and managed both in private and in public sectors, clinics usually cover the primary healthcare needs of populations in the local communities. On the other hand, the hospital segment is anticipated to grow with a CAGR of around 22% during the forecast period. A hospital is a healthcare institution that provides treatment to patients with a specialized team or medical and nursing staffs. Hospitals are also equipped with medical equipment that are used to treat the patients.

Dengue Vaccine Market Share
Get more information on this report: Request Sample PDF

Growth Highlights based on Region during 2018-2027

The global dengue vaccine market is segmented by regions into North America, Latin America, Europe, Asia Pacific and Middle East and Africa. Among these regions, the market of Asia Pacific dengue vaccine is driven majorly by China and India, where China is anticipated to hold the largest market share of around 30% share in the year 2027. Several outbreaks of dengue fever observed in the region over the years on the back of the region having a tropical environment, has raised the necessity of the government to increasingly focus on acquiring dengue vaccines in large quantity to address the massive population, which is majorly dominated by the two nations around the globe.

Further, Brazil, Mexico and Rest of Latin America are the prominent countries that are driving the growth of the Latin America dengue vaccine market. The Latin America region also has a tropical environment which is a favorable environment for the growth of the dengue disease. 

Dengue Vaccine Market Share


The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Market Drivers and Challenges

Growth Indicators

According to the estimations of the World Health Organization (WHO), around 100-400 million dengue infections occur each year and that half of the world’s population is now at risk. Further, it also stated that over the last two decades, the number of dengue cases reported to the organization has increased over fifteen-fold, reaching up to 3,312,040 numbers in the year 2015.

The alarming increase in the number of dengue cases around the world is a major concern for individuals as well as the government of the nations. Moreover, due to the unavailability of the vaccine for the disease during its outbreak, several numbers of cases have been self-managed resulting in the actual number of dengue cases being under-reported. Apparently, several developed and under-developed nations around the globe are also prone to this disease on the back of unplanned and uncontrolled urbanization, poor management and others. The increasing concern for the spread of dengue virus around the world along with huge government funding for the manufacturing of the dengue vaccine, which led to greater affordability of the vaccine, are some of the factors anticipated to drive the growth of the global dengue vaccine market.


Lack of awareness of the dengue vaccine as well as for the availability of the vaccine is anticipated to hamper the growth of the global dengue vaccine market.

Dengue Vaccine Market Share
Get more information on this report: Request Sample PDF

Top Featured Competitive Landscape

In The News

  • December 2018: One of the subsidiaries of Merck & Co., Inc. known as Merck Sharp & Dohme Corp. announced the collaboration with Instituto Butantan for the development of vaccines for dengue.

  • December 2018: Sanofi announced that the European Commission has granted marketing authorization for the dengue vaccine of Sanofi, known as Dengvaxia® in the European endemic areas.

Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the Dengue Vaccine market?

Ans: Increasing incidences of dengue fever worldwide along with the need to vaccinate the infected individuals are some of the major factors that are driving the growth of the market.

2) What would be the CAGR of Dengue Vaccine market over the forecast period?

Ans: The market is anticipated to attain a CAGR of around 22% over the forecast period, i.e. 2019-2027.

4) Which region will provide more business opportunities for growth of Dengue Vaccine market in future?

Ans: The market in Latin America is anticipated to provide more business opportunities in the future.

5) Who are the major players dominating the Dengue Vaccine market?

Ans: The major players in the global dengue vaccine market are Merck & Co., Inc., Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited and Institut Pasteur.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the major segments in the global dengue vaccine market?

Ans: The market is majorly segmented by age group, by end user and by region.

8) What can be the significant growth opportunity for the age group segment in the global dengue vaccine market?

Ans: The >12 years segment, which is a sub-segment of the age group segment, is anticipated to hold the largest market share of around 54% in the year 2027.

8) What are the restraining factors for the market?

Ans: Lack of awareness for the availability of dengue vaccines is one of the major factors anticipated to act as a barrier towards the growth of the global dengue vaccine market.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Request Research Report Sample